Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

Tiotropium Respimat® improved lung function in children with asthma aged 6-17 and is ...


- 6 Septembre 2016 modifié le 1 Janvier 1970


  • New CanoTinA-asthma® trial results showed adding tiotropium Respimat® improved lung function in children aged 6-111,2
  • Additional pooled data support the efficacy and safety of tiotropium Respimat® in children aged 6-173,4
  • Safety profile of tiotropium Respimat® in children aged 1-5 years is consistent with that in older children and adults5

(BUSINESS WIRE)-- Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma® trial that showed adding tiotropium Respimat® to maintenance asthma therapy significantly improved lung function, as measured by FEV1(0-3h), in children aged 6-11, compared to placebo (p<0.0001). ...

Source : http://me-newswire.net//news/18592/en...



ACTUALITES | INTERNATIONAL | TCHAD | POLITIQUE | CULTURE | EXCLUSIF | Revue de Presse | English News | 中國